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Stem cells have been recognized and intensively studied for their potential use in restorative approaches for
degenerative diseases and traumatic injuries. In the central nervous system (CNS), stem cell-based strategies
have been proposed to replace lost neurons in degenerative diseases such as Parkinson’s disease, Hunting-
ton’s disease, and amyotrophic lateral sclerosis (Lou Gehrig’s disease), or to replace lost oligodendrocytes
in demyelinating diseases such as multiple sclerosis. Stem cells have also been implicated in repair of the
adult spinal cord. An impact to the spinal cord results in immediate damage to tissue including blood vessels,
causing loss of neurons, astrocytes, and oligodendrocytes. In time, more tissue nearby or away from the
injury site is lost due to secondary injury. In case of relatively minor damage to the cord some return of
function can be observed, but in most cases the neurological loss is permanent. This review will focus on
in vitro and in vivo studies on the use of bone marrow stromal cells (BMSCs), a heterogeneous cell popula-
tion that includes mesenchymal stem cells, for repair of the spinal cord in experimental injury models and
their potential for human application. To optimally benefit from BMSCs for repair of the spinal cord it is
imperative to develop in vitro techniques that will generate the desired cell type and/or a large enough
number for in vivo transplantation approaches. We will also assess the potential and possible pitfalls for use
of BMSCs in humans and ongoing clinical trials.
Key words: Bone marrow stromal cell (BMSC); Spinal cord injury; Implantation; Regeneration;
Clinical trial
INTRODUCTION embryology, this “determination” of the stem cells is
thought to be an irreversible process. Recently, it has
become clear that the determined stem cell is in factStem cells are defined by their capacity for self-
renewal and differentiation into different cell types (87, phenotypically plastic and is able to give rise to cells
from different germ layers, a process known as transdif-89,94). In the early embryonic phase, stem cells are toti-
potent but after a few divisions the cells are determined ferentation (10,45,66,67,71).
Because of their versatility, stem cells have gainedto become specific for one of the three germ layers: the
ectodermal layer, which will give rise to skin and neural ample attention over the last years for their potential in
replacement/repair approaches. However, the term “stemtissue; the mesodermal layer, which will give rise to
connective tissue, muscle, bone, and blood cells; and the cells” has been used loosely without clear and appro-
priate criteria that define the used cell types. For exam-endodermal layer, which will give rise to gastrointestinal
tract and internal glandular organ cells. In the classic ple, CNS-derived neurospheres have been used exten-
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sively as a source for neural stem cells (NSCs), whereas ther isolate subpopulations and thus study a heteroge-
neous cell population that includes true stem cells asit is now clear that they are in fact heterogeneous cell
populations consisting mostly of neural progenitors and well as precursor and progenitor cells. Therefore, we
propose that “bone marrow stromal cells” is the properprecursors (i.e., cells that are already directed towards
the neural lineage). Recently, Parker and colleagues (82) terminology for this collection of cells. We oppose that
they are referred to as stem cells unless proper attemptselegantly demonstrated an overlap of 18% of stemness
genes between CNS-derived neurospheres and the C17.2 have been made to isolate a homogenous subpopulation
of clonally related cells that express known “stemness”NSC clone, which fulfills the in vitro and in vivo opera-
tional definition of a stem cell (82,98,104). Interestingly, genes such as Nanog, Oct-4, and Myc. Moreover, we
concur with Parker and coworkers (82) that stem cellsthis percentage of overlap increased twofold when the
C17.2 NSC clone was cultured as a neurosphere, reflect- in general are best defined operationally. Thus, the term
“stem cell” can only be applied when the cells are multi-ing a shift from a “stem-like” to a “differentiated” gene
expression pattern (82). potent, able to populate a developing area or repopulate
an ablated or degenerated area with appropriate cellThe stroma of bone marrow houses multipotent cells
that can differentiate into lineages of blood cells, stromal types, able to be serially transplanted, and able to self-
renew. For a more in-depth discussion on this opera-and skeletal tissue (24,25,33,58). It has been reported
that these stem cells can also transdifferentiate into liver tional definition for stem cells we refer to a previous
publication (82).cells (84), skeletal (29,108) and cardiac (62,79) muscle
cells, and CNS cells (6,14,29,48,53,66,91), but this is
HARVEST AND CULTURING OF BMSCsstill debated [among others (17,109)]. Bone marrow is
relatively easy to obtain, which circumvents the ethical Although some small variations exist, BMSCs are
harvested according to largely similar protocols amongconcerns that surrounds the use of embryonic stem cells.
Because of its availability and its reported aptitude to the many groups studying these cells for their potential
in a variety of therapeutic approaches. Bone marrowtransdifferentiate, stem cells from bone marrow are
thought to serve as an alternative source for other types cells are usually removed from long bones such as the
femurs and tibiae by flushing with cold phosphate-of stem cells that are needed for specific therapeutic ap-
proaches. buffered saline with low percentage of fetal bovine se-
rum. These cells are washed and cultured in Dulbecco’sAs with stem cells in general, there is much confu-
sion regarding the correct terminology and abilities of modified Eagle’s medium or Iscove’s modified Dulbec-
co’s medium with 10–20% fetal bovine and/or horse se-cells derived from bone marrow. These cells have been
referred to as “bone marrow stromal cells (BMSCs)” or rum. After 3–5 days in culture, nonadherent cells,
mainly red blood cells that have a short life span of“stromal cells,” because they reside in the stroma of
bone marrow, or as “bone marrow stem cells” or “bone about 72 h in these culture conditions, are removed, and
the remaining cells washed and further cultured in themarrow-derived stem cells,” because a percentage of the
cells have stem cell abilities. The cells have also been same medium. Usually within 2 weeks after initiation,
the cultures consist of spindle-shaped cells with somereferred to as “mesenchymal stem cells” or “bone mar-
row-derived mesenchymal stem cells,” because of their monocytes and macrophages present (6,60). The adher-
ent cells are removed by trypsinization and then replatedorigin from the mesodermal germ layer. Due to this con-
fusing terminology it is difficult to have a clear under- for further expansion or used experimentally. These par-
ticular cells (i.e., the plastic adherent cells) are consid-standing of the true identity of the cells used in the vari-
ous studies. In addition, their ability to differentiate or ered to be “the BMSCs.” Generally these cells are not
further phenotypically characterized. However, severaltransdifferentiate is unclear due mainly to the large vari-
ety of induction protocols used by different groups. For groups did analyze the presence of a battery of surface
antigens and with great consistency demonstrated theexample (see also below), one group reported that about
1% of human and mouse BMSCs can be induced into presence on human BMSCs of MHC class I, CD13,
CD44, CD63, CD73, CD29, CD90, CD105, and CD166the neural lineage (91), whereas another group using a
different induction protocol reported that 80% of human and the absence of MHC class II, CD14, CD45, and
CD34 (118). Several other surface antigens (i.e., SH2,and rat BMSCs could become neural cells (113). Clearly,
different protocols lead to highly variable results and SH3, CD71, CD120a, and CD124) have been described
for rat BMSCs (116).this makes it difficult to fully understand the abilities of
the BMSC and thus its potential for therapeutic ap- With this in mind we reviewed the literature on the
use of BMSCs (harvested as described above) for repairproaches.
The majority of groups working with cells derived of the spinal cord. We will focus primarily on the appli-
cation of BMSCs and not only the stem cell fractionfrom the stroma of bone marrow do not attempt to fur-
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thereof. Nevertheless, through transdifferentiation the ability of BMSCs to give rise to neural cells, it is imper-
ative to investigate and optimize the culture conditionsstem cell portion and possibly the precursors and pro-
genitors after dedifferentiation can give rise to cells that are necessary for this transdifferentiation. Padovan
and coworkers (80) demonstrated that human BMSCsfrom the neural lineage: neurons, astrocytes, and oligo-
dendrocytes. Especially for smaller focal traumatic and proliferated best and expressed the highest percentage
of β3-tubulin (about 27% of the total population) whendemyelinating lesions it could be beneficial to acquire
neural cells from BMSCs in vitro prior to transplantation cultured in the presence of 20% fetal bovine serum and
10 ng/ml basic fibroblast growth factor (bFGF or FGF-into the spinal cord or manipulate them in vivo such that
they can replenish lost neural cells. 2). With fibronectin as a growth substrate this percent-
age was further increased to approximately 48% (80).
DIFFERENTIATION OF BMSCs INTO BDNF or neurotrophin-3 (NT-3) elicited the expression
NEURAL LINEAGE IN VITRO of β3-tubulin up to over 40% of the cells, which could
not be further increased by combining them with FGF-To get a better understanding of the true nature of
BMSC-derived astrocytes, oligodendrocytes, and neu- 2 (80). With these culture conditions, the cells did not
express NeuN. In the same medium but without serum,rons it is imperative to define criteria for each of them.
Is it acceptable to merely assume that cells that express about 10% of the cells differentiated into GFAP-positive
astrocytes (80). Unfortunately, the authors did not fur-markers specific for a particular neural cell will also
have relevant functional properties or should it be a re- ther combine these different culture conditions to possi-
bly enhance the induction of BMSCs to differentiate intoquirement to demonstrate this at least in vitro? The ex-
pression of certain molecules has been accepted as an neuronal-like cells.
Although the study of Padovan and colleagues (80)indication of differentiation into a particular neural cell
type. Astrocytes express glial fibrillary acidic protein may suggest that serum is necessary for neural induc-
tion, nestin-positive neural precursor cells were found in(GFAP) and oligodendrocytes express rat insulin pro-
moter (RIP) and myelin-basic protein (MBP). Neurons serum-free culture conditions (111). These nestin-posi-
tive cells differentiated into GFAP-positive astrocytesare identified by the presence of βIII-tubulin (immature
neurons), neuronal marker N (NeuN), neuron-specific (based on morphology; 40% of the population) or
NeuN-positive neuronal-like cells (19%) after 5 daysenolase (NSE), neurofilaments (NF), and microtubule
associated protein-2 (MAP-2). However, the expression in coculture with cerebellar granule cells (112). The
groups mentioned above reported elegant and compre-of cell-specific markers alone is not adequate and, ex-
cept for astrocytes, morphological characteristics that hensive studies. Unfortunately, a general consensus for
culture conditions for neural induction of BMSCs hasare in apparent agreement with a specific cell type can
be misleading [see (56) vs. (113)]. Indisputably, the best not yet been established.
A number of studies have shown that BMSCs can becriteria for a BMSC-derived neural cell are its functional
properties, which unfortunately is much easier to dem- induced to become neural-like cells in vitro by adding
growth factors (2,44,72,73,80,90,91,100), dibutyrylonstrate in vitro than in vivo. Nevertheless, unless
BMSC-derived cells positive for RIP or MBP myelinate cAMP (26), or chemical agents as β-mercaptoethanol
and dimethyl sulfoxide in combination with butylatedcentral axons in vitro, their designation as oligodendro-
cytes should be taken with caution. Similarly, unless hydroxyanisol (11,113,114). Using these various induc-
tion protocols, 2-76% of the cells became neural-likeBMSC-derived cells positive for neuronal markers have
appropriate electrophysiological properties their desig- cells. These results may indicate that depending on the
growth factor the same intracellular pathway resulting innation as neurons should be carefully considered. In line
with this, we propose to use the additive -like for cells neural induction gets differentially activated. However,
more likely is that the different growth factors exert theirthat express particular markers but have not been func-
tionally characterized. We believe that this would better activity through different intracellular pathways that re-
sult in different degrees of neural induction.reflect the uncertainty of the true nature of the particular
cell. Padovan and colleagues (80) investigated whether
among BMSCs there is a subpopulation that can moreSeveral groups have reported that BMSCs can differ-
entiate into cells that express neuronal markers or into easily differentiate into the neural lineage. They com-
pared unsorted BMSCs and a population of BMSCs sor-cells that have a neuron-like morphology (14,67,68,80,
91,92). Figure 1A demonstrates rat BMSCs isolated and ted on the presence of CD133 on their membrane and
demonstrated that a higher percentage of the latter wascultured according to earlier described methods (6).
When brain-derived neurotrophic factor (BDNF) is able to express neural markers. This phenomenon was
also demonstrated by comparing gene expression pat-added to the culture, the presence of neuronal-like cells
can be observed (Fig. 1B). To benefit most from the terns of the different subpopulations of BMSCs cells
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Figure 1. (A) Undifferentiated rat BMSCs 7 days in culture expressing green fluorescent protein (GFP). The cells were isolated
and cultured according to a previously described protocol (6) and infected with lentiviral vectors encoding GFP. Addition of brain-
derived neurotrophic factor pushes the BMSCs into neural-like cells (B).
(13,58). Although this particular population of CD133- of neurons, which is approximately −70 mV. Jiang and
colleagues (41,42) cultured BMSC-derived neuron-likepositive cells, or cells derived thereof, were not further
defined functionally, these results make it clear that the cells long term with different mitogens and cytokines,
then cocultured them with fetal mouse brain astrocytesBMSC population when obtained as described above is
a heterogeneous cell population. and demonstrated that the neuronal-like cells had a Vrest
between −8.4 and −55.4 mV. These authors also demon-Interestingly, and strongly emphasizing that more
complete criteria are imperative to define BMSC-derived strated that prolonged coculture with the fetal astrocytes
resulted in a further decrease of the negative restingneuronal cells, Lu and coworkers (56) demonstrated that
the neuron-like cells derived from BMSCs by adding β- membrane potentials. Moreover, these cells were then
able to fire action potentials (41,42). Regrettably, thismercaptoethanol to the culture medium (11,113,114) are
actually dying cells. Time-lapse microscopy revealed study did not investigate the potential of these cells to
fire trains of action potentials, a characteristic of fullythat the cellular extensions protruding from the cells are
merely a result of cellular shrinkage. Lu and colleagues matured neurons (16).
Electrophysiologically active cells derived from(56) took this investigation one level further and demon-
strated that these morphological changes of the BMSCs BMSCs were also described by Wislet-Gendebien and
colleagues (112). They reported that after 4–6 days inwere actually due to cellular toxicity. They showed that
cells exposed to several stressors, such as detergents, culture some of the cells demonstrated sensitivity to the
neurotransmitters GABA, glycine, serotonin, and gluta-chloride, and extreme pH, exhibited the same morpho-
logical characteristics (i.e., neuronal-like cells) as the mate, possessed an outward K+ current but no inward
Na+ current, and exhibited a Vrest of about −37 mV.BMSCs cultured in the presence of β-mercaptoethanol.
Clearly, neural cells obtained in vitro from BMSCs need These characteristics correspond with those described
for neurons in stage 1 of their maturation (16). Wislet-to be functionally characterized. In the case of BMSC-
derived neurons, demonstrating appropriate electrophys- Gendebien and colleagues (112) further showed that
after 7–15 days in culture the cells were able to fire aiological behavior is crucial.
single-spike action potential and had acquired Vrest of
ELECTROPHYSIOLOGICAL ACTIVITY
−56 mV [characteristics that corresponded to neurons in
OF BMSC-DERIVED NEURON-LIKE CELLS stage 2 of their maturation (16)]. These findings are ex-
citing and demonstrate that cells within the BMSC pop-So far only a few groups published in vitro evidence
that BMSC-derived neuron-like cells have electrophysi- ulation can differentiate in maturation stage 2 neurons
when cultured under the appropriate conditions. It is un-ological activity appropriate for neurons (41,42,48,112).
Kohyama and colleagues (48) demonstrated that such fortunate that Wislet-Gendebien and coworkers (112)
could not demonstrate the presence of fully mature neu-cells exhibited a resting membrane potential (Vrest) of
−20 and −50 mV at 14 and 28 days in vitro, respectively. rons [stage 3 (16)], which are able to fire trains of spikes
and exhibit a normal Vrest of −70 mV. The results fromThis was the first study that demonstrated that BMSC-
derived neuron-like cells acquire a Vrest resembling that the studies mentioned above indicate that in vitro the
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BMSC-derived neuronal-like cells acquire a more nega- ery can be achieved by addressing several key areas:
prevention of injury-induced cell death (neuroprotec-tive Vrest in time. Perhaps they could have succeeded in
creating fully matured neurons if they had cultured their tion) close and away from the injury, promoting axonal
regeneration by decreasing the inhibitory nature of thecells for longer than 15 days. The differentiation of
BMSCs into fully mature neurons in vitro remains one environment at the injury site or by increasing the intrin-
sic ability of injured neurons to grow their axon, andof the more intriguing challenges in the field of stem
cells and CNS repair. promoting myelination of regenerated axons and demye-
linated intact axons. It appears that a combination of
DIFFERENTIATION OF BMSCs these approaches followed by intensive rehabilitation to
INTO NEURAL LINEAGE IN VIVO develop and stabilize new axonal circuits will be neces-
sary. Moreover, the interventions need to be applied si-The first study that provided evidence that BMSCs
can differentiate into neural-like cells in vivo was from multaneously and/or successively, thereby creating opti-
mal conditions for morphological and functional repair.Mezey and Chandross (67). Using a mouse model, they
transplanted male bone marrow cells into the peritoneal A typical feature of the injured cord is the progres-
sive loss of the central gray and peripheral white mattercavity of female recipients. The grafted bone marrow
cell preparation did not contain neuron- or glia-like cells creating large fluid-filled cysts. To provide axons with
a substrate to grow across these cavities, transplantationat the time of transplantation, although it should be
noted that about 18% of the cells expressed the neural of cells has been widely explored. Many cell types,
alone or in combination, have been investigated over theprecursor cell marker nestin, when cultured for several
weeks. Using in situ hybridization techniques, Y chro- last decades (15,88). Over the last years, the potential
beneficial use of BMSCs in restorative approaches ofmosome-containing neurons were located in the brain of
the host, suggesting that the grafted BMSCs had crossed the spinal cord has attracted ample attention. Table 1
provides an overview of studies in which BMSCs werethe blood–brain barrier and formed neurons within the
CNS. applied into the damaged spinal cord and the results that
were obtained. Clearly, among these studies some re-Interestingly, Cogle and colleagues (23) also demon-
strated Y chromosome-containing neurons that were sults are confusing and in disagreement with each other.
For optimization of BMSC transplantation paradigmsnicely integrated in the hippocampus of three female hu-
mans that had received transplants of male bone marrow for application in clinical trials several crucial questions
regarding cell survival, migration, neuroprotection, axo-cells up to 6 years earlier. It should be mentioned that a
fusion between a grafted BMSC and a host cell could nal regeneration, and functional recovery need to be ad-
dressed.result in false-positive results. In several studies it has
been reported that BMSCs can spontaneously fuse with
Cell Survivalother cells in vitro (105,117). Whereas this is a real pos-
sibility, Cogle and coworkers (23) used fluorescence in An essential aspect for successful cell transplantation
approaches is survival of the grafted cells. In vitro,situ hybridization techniques to reveal the presence of
only one X chromosome, concluding that in their study BMSCs are cultured in medium containing 10–20% se-
rum. Factors other than present in serum are not essen-the neurons could not have been the result of cell fusion.
The Y chromosome-containing, transgender cells ac- tial for their survival and proliferation. In fact, addition
of growth factors such as BDNF, FGF-2, or NT-3 insti-counted for approximately 1% of all neurons and 1–2%
of all astrocytes and microglial cells in the hippocampus. gates differentiation of the BMSCs into neural-like cells
(80) rather than affecting survival. In vivo, in a rat con-These studies provide exciting evidence that BMSCs can
migrate across the blood–brain barrier and differentiate tusion injury model, Hofstetter and colleagues (36)
showed that more BMSCs survived when transplanted 1into neural cells in the mature CNS, which is promising
for the use of BMSCs in CNS reparative approaches. week after injury compared to immediately after injury.
The surviving cells were located within trabeculae that
BMSCs FOR SPINAL CORD REPAIR span the injury site (22,36). However, with the 1-week
delay only 1% of the cells (about 3000 total) survivedSpinal cord injury results in cell death, axonal dam-
age, progressive loss of tissue, and impaired motor and at 4 weeks after grafting, and although this is an increase
over the percentage of cells that survived immediatesensory functions. Some restoration of function has been
reported resulting from endogenous self-repair processes transplantation (<0.15%), the total number of surviving
cells was very low (36).or from applied interventions. At present, due to the lack
of repair approaches that cause meaningful functional It has been proposed that one of the mechanisms un-
derlying death of cells transplanted into the spinal cordrestoration, spinal cord injury results in a wheelchair-
bound life. In general it is thought that functional recov- is injury-induced inflammation (103). The cellular and
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Table 1. Literature on Transplantation of BMSCs In Vivo in Spinal Cord Injury Models
Authors In Vitro
(Reference) Source Modified Injury Model Number of Cells Main Results Additional Results
Chopp et al. rat no Contusion at T9 250,000 Significantly im- Upregulation of nes-
(22) level. Cells proved motor out- tin in ependymal
grafted 7 dpi. Sur- come at 2 weeks. and associated
vival 5 weeks. cell layers.
Hofstetter et al. rat no Contusion at T9 300,000 Transplanted BM- Better BMSC sur-
(36) level. Cells SCs form guiding vival with de-
grafted immedi- strands at the in- layed grafting (7
ate or 7 dpi, 2 jury site. dpi). Motor out-
mm rostral and come improved at
caudal. Survival 5 5 weeks.
weeks.
Akiyama et al. mice no EB-X lesion* T10 5,000 Remyelination of
(3) level. Cells demyelinated ax-
grafted 3 dpi. ons after BMSCs
Rats were immu- transplantation.
nosuppressed.
Survival 3 weeks.
Corti et al. (24) mice no Cells injected in tail 10,000,000 Systemically infused
vein after X-irra- BMSCs migrate
diation. Survival towards spinal
3 months. cord.
Inoue et al. (40) rat no EB-X lesion* lum- 100,000–10,000,000 Remyelination of More myelinated ax-
bar spinal cord. demyelinated ax- ons with focal in-
Cells grafted 3 ons after BMSCs jection. Focal ap-
dpi, systemic or transplantation. plication more
focal. Survival 3 efficient.
weeks.
Lee et al. (51) mice no Contusion at T11 3,000 Neural differentia-
level. Cells tion: BMSCs dif-
grafted 7 dpi in ferentiate into
and 2 mm rostra- neurons in the
lly to injury. Sur- brain and astro-
vival 4 weeks. cytes in the cord.
Wu et al. (115) rat no Contusion injury T9 1,000,000 Neuroprotective: BMSCs survival de-
level. Cells significant reduc- creased in time
grafted immedi- tion of cavity vol- up to 3 weeks.
ately. Survival 1, ume. Motor outcome
2, 3, 4 weeks. significantly im-
proved up to 14
dpi.
Ohta et al. (77) rat no Contusion injury T9 5,000,000 Neuroprotective: re- Significant improve-
level. Immediate duction of cavity ment of motor
cell grafting in volume with outcome after 5
CSF (4th ventri- 47%. weeks. BMSCs
cle). Survival 5 migrated to cord.
weeks.
Ankeny et al. rat no Contusion injury T9 60,000 Neuroprotective: No significant im-
(4) level. 2 dpi trans- BMSCs reduce provement in mo-
plantation of cells cavity volume. In- tor outcome after
into lesion cavity. creased spared tis- 8 weeks.
Survival 8 weeks. sue volume and
white matter.
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Table 1. Continued
Authors In Vitro
(Reference) Source Modified Injury Model Number of Cells Main Results Additional Results
Lu et al. (55) rat no BMSCs-NT3 into 200,000 Axonal regenera-
lesioned dorsal tion: cAMP and
column 5 days NT-3 combined
after cAMP in L4 promoted axonal
DRG and NT3 growth of sensory
immediate rostral axons.
to graft. Survival
3 months.
Satake et al. rat no Contusion T9–10 1,000,000 Homing of trans- Some BMSCs dif-
(93) level. 3, 5, 7 dpi planted cells to- ferentiated into
cell injection lum- wards lesion area. nestin-positive
bar subarachnoid immature neu-
space. rons or glial cells.
Zurita et al. rat no Contusion at T7 1,000,000 Significant improve- BMSCs survive and
(119) level. Cells ment in motor form bridges in
grafted 3 months outcome (BBB) the cavity.
postinjury at le- after 2 weeks in
sion site. Survival the chronically in-
4 weeks. jured rat.
Sigurjonsson human no In ovo surgery and 20,000 Grafted cells indis- During differentia-
et al. (95) cell implantation tinguishable from tion loss of CD34
in chicken em- neurons chick and expression by
bryo (stage 15– also electrophys. BMSCs.
16). Suvival 4–9 active.
days.
Lu et al. (57) rat yes† Dorsal column le- 100,000 Neural induced cells BDNF secreting
sion C3. Survival in vitro do not ex- BMSCs led to
up to 3 months. press neural higher axon den-
markers in vivo. sity. No change
in motor outcome
at 3 months.
*EB-X lesion = ethylbromide injection with X-irradiation to create a demyelinating injury.
†BMSCs were neurally induced following the procedure described by Woodbury et al. (114) and modified to express BDNF.
molecular components of the inflammatory response 60), BDNF (20,50,60), and, albeit in smaller amounts,
FGF-2 (60). These factors may have pronounced effectscould initiate cell death (9), which would also explain
improved survival with delayed grafting paradigms. If on repair-related processes such as neuroprotection and
axonal outgrowth, but they may also affect BMSC sur-this were the case, grafting into a chronically injured
cord would further improve cell survival. Unfortunately, vival and/or proliferation in vivo through an autocrine
action (116). If this is the case why then do BMSCsso far there have been no conclusive results on their
survival rate in the chronically injured spinal cord. In survive poorly within the injured spinal cord? It is possi-
ble that the grafted BMSCs simply do not secreteone study, BMSCs grafted into a contusion site at 3
months after injury reportedly survived an additional 4 enough of the necessary growth factors to positively ef-
fect their own survival within an extremely harsh injuryweeks but actual numbers were not provided (119).
From the data so far, it has become clear that the sur- milieu with many cells and factors that negatively influ-
ence survival. Also, there may be batch-to-batch differ-vival of the BMSCs is compromised after transplanta-
tion into the injured spinal cord. ences in the ability to produce growth factors, which
was demonstrated for human BMSCs (74) and thatSeveral recent publications have reported that in vitro
BMSCs produce and secrete a variety of growth factors could result in highly variable results masking the true
potential of BMSCs to survive the spinal injury milieu.such as glial cell line-derived neurotrophic factor
(GDNF) (31,116), nerve growth factor (NGF) (31,50, Clearly, for the development of safe and effective
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clinical application the survival of BMSCs after trans- are truly capable of migration within the injured spinal
cord has not explicitly been answered. Future researchplantation into an injury has to be improved. Especially
when the cells also function to deliver factors that are should focus on these questions because the outcome is
crucial for the design of BMSC transplantation para-most likely necessary to optimize the neuroprotective
and axonal regeneration response. Future research digms for clinical application to repair the injured spinal
cord.should concentrate on decreasing death of BMSCs
within the lesion area, possibly by elevating local levels
of growth factors essential for survival or by preventing Neuroprotection
the upregulation of apoptotic molecules or promoting Although grafting cells into the injured spinal cord is
the expression of antiapoptotic molecules.
typically applied to generate a growth response, a neuro-
protective effect can also be observed (102). Repeatedly,Cell Migration
it has been demonstrated that cellular grafts limit theAre BMSCs able to migrate towards or away from loss of nervous tissue in the injured cord (86,102). In
the site of injury/transplantation? In vitro studies have fact, in animal models of spinal cord injury, improve-
shown that BMSCs express CXCR4, the receptor for the
ments in motor performance seen after cell transplanta-
chemokine CXCL12 [also known as stromal-derived
tion are often contributed to neuroprotection rather thanfactor-1, SDF-1 (5)]. CXCL12 has been implicated in
axonal regeneration. Grafting BMSCs into the contused
cell migration, possibly through the extracellular signal-
adult spinal cord also promotes tissue sparing, which
regulated kinase (ERK) and Akt phosphorylation path-
was evidenced by smaller cavities and preserved host
ways (12,30). Interestingly, under some pathological
white matter (3,4,77).
conditions reactive astrocytes produce CXCL12 (12,69). It is likely that the mechanism underlying the neuro-It is possible that following spinal cord damage upregu- protective effect of BMSC transplants is related to thelation of the level of CXCL12 attracts CXCR4-positive
ability of the cells to produce and secrete factors thatBMSCs towards the injury site. This could be the mech-
either arrest and/or prevent the onset of cell-destructive
anism at the basis of the homing of BMSCs into spinal
events. BMSCs are known to produce and secrete GDNF
cord injury sites. However, at this time it is not known (31,116), NGF (31,50,60), BDNF (20,50,60), and FGF-
whether this particular chemokine is present within the 2 (60). These factors have all been implicated in neuro-injured spinal cord. protective effects. NGF and BDNF increase survivalIn vivo, systemically administered BMSCs have been (32,106) and decrease apoptotic death of neurons and
reported to migrate towards injury sites in the brain
oligodendrocytes (97). BDNF also increases oligoden-(51,54,59,73), but the results regarding homing towards drocyte proliferation (64). GDNF has been implicated in
the injured spinal cord have been conflicting. Recently,
the rescue of motor neurons (8,21), possibly by activat-111In-oxine-labeled BMSCs were shown to migrate ing MAP kinase and Bcl-2, an antiapoptotic regulatorpoorly towards the injured spinal cord following intrave- (21). FGF-2 is known to positively affect tissue sparing
nous administration (25). On the other hand, BMSCs (43,65) and promote neuronal survival and angiogen-labeled with iron oxide microbeads were detected using
esis (65) following spinal cord injury. Another molecule
magnetic resonance imaging within a spinal cord com- produced by BMSCs that could positively influence tis-pression injury after intravenous administration (101).
sue sparing is VEGF, a potent angiogenic factor (34).Satake and coworkers (93) demonstrated that BMSCs
grafted into the lumbar subarachnoid space aggregated
Axonal Regenerationonto the cord near a thoracic contusion injury site and
that a few migrated into the contusion injury. Possibly, In a few studies the axonal regeneration-promoting
abilities of BMSCs have been addressed. Lu and co-the meninges may have prevented more BMSCs to mi-
grate into the spinal cord parenchyma. Obviously, if workers (57) demonstrated that transplantation of native
BMSCs into the contused spinal cord promoted modestBMSCs are able to migrate towards an injury site in the
adult spinal cord, it would allow for systemic delivery sensory and motor axon regeneration, whereas grafting
of neurally induced BMSCs did not result in axonof the cells, thereby avoiding invasive transplantation
strategies. growth. One explanation for the failure of the neurally
induced BMSCs to promote axonal regeneration in theMigration of transplanted BMSCs away from an in-
jury site in the spinal cord might be beneficial for out- injured spinal cord is that these cells die soon after trans-
plantation. The neural induction of the BMSCs was per-growth of regenerating axons. It was reported that such
migration did not occur in a contusion injury model formed according to an earlier described method (11,
113,114), which, as had been already recognized by Lu(25). However, at present, the question whether BMSCs
BMSCs FOR SPINAL CORD REPAIR 571
and colleagues (56), causes BMSCs to die rather than difficult for fore/hindlimb coordination. This affects the
proper assessment of hindlimb motor performance. Otherbecome neuron-like cells.
An alternative explanation for the lower axonal sensorimotor tests such as foot print, grid and beam
walking, and analysis of gait using the CatWalk pro-growth response observed by Lu et al. (57) is that neu-
rally induced BMSCs are less effective in eliciting such vide a more complete measurement of hindlimb func-
tion. In addition, it was unfortunate that these particulara response than undifferentiated BMSCs (for instance,
because they produce and secrete less growth-promoting studies (22,115,119) did not investigate whether the im-
provements in behavior were associated with an axonalfactors). At present it is known that BMSCs produce and
secrete several growth factors. However, it is unknown regeneration response. Considering that in these studies
the observed functional improvements appeared rela-whether neurally induced BMSCs actually produce
growth factors or whether they do so but in lower tively soon after injury and transplantation, it seems that
neuroprotective mechanisms (3,4,77), possibly throughamounts than undifferentiated BMSCs. Indirect evi-
dence that the neurally induced BMSCs do not produce secretion of growth factors rather than axonal regenera-
tion responses (55–57), were at the basis of the improve-enough growth factors to stimulate axonal regeneration
was provided in two studies demonstrating that trans- ments.
So far studies on behavioral effects following intras-plantation of neurally induced BMSCs genetically modi-
fied to produce and secrete BDNF did improve the pinal transplantation of BMSCs have used a variety of
models in different species. In mice or rat different num-axonal growth response (57,59). In another study, a mul-
tifaceted and intriguing spinal cord injury/regeneration bers of BMSCs were grafted acutely into the cervical
(57) or thoracic spinal cord (4,36,115), or subacutelymodel was used to investigate the regeneration-promot-
ing capacity of BMSCs (55). BMSCs modified to se- (22) or chronically (119) in the thoracic spinal cord.
Most models involved a contusion injury (4,22,36,115,crete NT-3 were transplanted in a transection injury of
the midthoracic dorsal columns 1 week after administra- 119), others a partial transection model (57). The sur-
vival period after transplantation as well as the studiedtion of cAMP into the L4 dorsal root ganglion as a pre-
conditioning stimulus for the sensory neurons. This was end points varied among these studies. Given the major
differences between these approaches, it is difficult tothen combined with injection of NT-3 after injury/graft-
ing within and beyond the injury site (55). The combina- compare the respective results and thus to properly value
the effects of BMSCs on functional recovery and axonaltion of all interventions resulted in regeneration of as-
cending sensory axons into and from the BMSC graft. regeneration in the injured spinal cord so far.
This brings up the question whether there should beEither cAMP or NT-3 administration alone did not result
in such an axonal response. These results suggested that one particular model that should be used uniformly by
groups that study the use of BMSCs in spinal cord re-a combinatorial approach that stimulates both the neural
soma and axon might effectively increase the axonal re- pair. Is there a best model? We do not support the idea
of only one model. In humans, the morphological andgeneration. Surprisingly, in the study of Lu and col-
leagues (55) application of cAMP alone at the level of functional outcome following spinal cord injury is highly
variable. Nervous tissue loss, axonal dieback, neuronalthe sensory neurons did not result in improved sensory
growth, while it had been implicated in such a response death, and scar formation depend largely on factors such
as the site and degree of injury and the postinjury care.earlier (75) as well as in other types of axonal regenera-
tion responses (83). Clearly, as with many other promis- Applying one particular model will ultimately only ben-
efit a percentage of spinal cord injured patients. How-ing cell types for transplantation into the injured spinal
cord, more extensive studies need to be performed be- ever, one particular in vivo model can be superior to
another to answer a particular aspect of spinal cord in-fore BMSCs can be used effectively in repair strategies.
jury and repair. For instance, neuroprotective effects of
Functional Recovery BMSC transplants can best be addressed in contusion
injuries, whereas their effect on axonal regeneration isIt has been reported that BMSC results in significant
improvement of hindlimb locomotor performance when most reliably assessed in complete transection injuries.
The highly variable outcome after human spinal cordtransplanted in the acutely (115), subacutely (22), and
chronically (119) contused spinal cord. In all three stud- injury requires testing of BMSC transplantation (and of
other approaches) in a variety of in vivo injury models.ies hindlimb function was evaluated using the open-field
BBB test, which scores for joint movements, paw place- This would allow proper judgment as to whether follow-
ing a certain injury BMSC grafting or an alternative in-ment, weight support, and fore/hindlimb coordination
(7). Although a valid way to test hindlimb function, the tervention would be best. For understanding the poten-
tial of BMSCs for spinal cord repair it would be betterBBB test has limitations; the scoring is subjective and
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to have certain studies independently repeated to con- 76), Hurler’s syndrome and metachromatic leukodystro-
phy (47). Each of these trials has had various degrees offirm the results, which if that is the case, may establish
BMSC grafting as the type of intervention best suited success depending on the measured end points. A posi-
tive outcome from all of these trials is that only one offor a particular type of injury.
the 68 patients that entered in the studies mentioned has
CLINICAL APPLICATION OF BMSCs suffered any side effects (i.e., mild urticaria as a reaction
to the fetal bovine serum albumin in which the cellsThere is considerable experience with the harvesting
of BMSCs from the iliac crests of patients (46). In the were grown), indicating that BMSCs can be used safely
in clinical settings.clinic, following chemotherapy and/or radiation therapy,
the bone marrow microenvironment is damaged, result- There is considerable debate as to which patients with
a spinal cord injury would be the ideal candidates foring in diminished or delayed hematopoiesis (27,63). Al-
logeneic marrow transplants have been explored for re- testing cell types (including BMSCs) that have shown
potential for clinical applications. Human trials ap-constitution of the damaged marrow stroma, although at
present it seems that recipients of such transplants have proved by the US Food and Drug Administration (FDA)
require safety data prior to efficacy data. Consequently,only host-type marrow stromal cells after transplantation
(96,99). Also, BMSCs are more increasingly used for most cellular transplantation strategies tested in clinical
trials in the US have focused on patients with function-surgical approaches for spinal fusion or for degenerated
disc disease (70,110). ally complete spinal cord injuries (ASIA A; American
Spinal Cord Injury Association). However, for properBMSCs have several features that make them appeal-
ing candidates for transplantation after spinal cord injury evaluation of the efficacy of transplantation strategies
regarding functional improvements, patients with in-in the human, which include the facts that (a) they can
be relatively easily isolated under local anesthetic (46), complete lesions (represented by ASIA B–D) may be
more beneficial. Clinical trials transplanting BMSCs(b) human BMSCs can be rapidly and extensively ex-
panded in cell culture (6,14), (c) there is no evidence after spinal cord injury are ongoing in several countries,
including Korea, Mexico, Colombia, and Brazil. Otherthat they produce tumors in vivo, even after immortali-
zation to ensure an unlimited source of self-renewal ex than a Korean study (81), results from these trials have
not yet been published. In this particular study, six func-vivo (1,28), (d) they have demonstrated capacity for tis-
sue repair (3,57), and (e) they secrete growth factors tionally complete spinal cord injured (ASIA A) patients
received a BMSC transplant combined with the adminis-in vivo that can enhance regeneration/repair (19,20).
Clearly, BMSCs may be a good candidate for transplan- tration of granulocyte macrophage-colony stimulating
factor (GM-CSF). All patients were operated during thetation into the injured spinal cord. However, a concern
is the considerable variation existing among donors such first 2 weeks after injury and a total of 1.8 ml with a
density of 1.1 × 106 BMSCs/µl was injected at the epi-as gender, genetic background, and general health (74).
Therefore, we agree with Neuhuber and colleagues (74) center of a contusion lesion at 5 mm below the dorsal
surface. In five out of the six patients motor and sensorythat specific parameters need to be found that allow
rapid and reliable selection of BMSCs with therapeutic function improved, with four of the patients switching
from the ASIA A to the ASIA C level. Follow-up evalu-potential.
Based on the above-mentioned features of BMSCs, ations up to 18 months after transplantation revealed no
serious complications. Although these results are verythere is much excitement about the potential use of these
cells for spinal cord repair. However, it is also clear that promising, detailed information concerning neurological
examination is lacking. Further studies in this arena willBMSC are not the so-called “silver bullet,” the one ther-
apy that will promote regeneration and restore function need to focus on reproducibility, safety, and finally effi-
cacy.in the injured spinal cord. In fact, it is generally accepted
in the field of spinal cord injury and repair that such a
CONCLUDING REMARKS
“silver bullet” does not exist. Spinal cord injury is par-
ticularly complex and involves a variety of histopatho- Studies on the ability of BMSCs to transdifferentiate
in vitro into the neural lineage often use different proto-logical destructive and sometimes constructive events.
A treatment for spinal cord injury aimed at repair of cols [e.g., (91) vs. (113)]. This leads to a great deal of
confusion on the true capacity of these cells and thusfunction needs to deal with all of these events in a
timely, most likely sequential, fashion. their therapeutic potential. There is a clear need for a
consensus on how to induce BMSCs into the neural lin-There have already been several clinical trials that
have used intravenous administration of BMSCs for spe- eage in vitro. Moreover, this procedure and in particular
alternative ones that claim a higher efficiency need tocific diseases such as patients with malignancies (52),
but also efficacy trials in osteogenesis imperfecta (18,37, be repeated independently. Also, there is a need for stan-
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cells into neuron-like cells after co-culture with hippo-dardized criteria [operational definition (82)] that will
campal slice. Brain Res. 1029:114–119; 2004.result in the proper designation of BMSC-derived cells 3. Akiyama, Y.; Radtke, C.; Kocsis, J. D. Remyelination of
as neurons or oligodendrocytes. Only then will it be pos- the rat spinal cord by transplantation of identified bone
sible to optimally benefit from the therapeutic potential marrow stromal cells. J. Neurosci. 22(15):6623–6630;
2002.of BMSCs for spinal cord repair.
4. Ankeny, D. P.; McTigue, D. M.; Jakeman, L. B. BoneIn vivo, the use of BMSCs in spinal cord injury mod-
marrow transplants provide tissue protection and direc-els is still relatively new (see Table 1) and many ques-
tional guidance for axons after contusive spinal cord in-
tions remain unanswered. Some of these questions are: jury in rats. Exp. Neurol. 190:17–31; 2004.
To what extent do BMSCs survive when grafted into the 5. Auiti, A. T.; Webb, I. J.; Bleul, C.; Springer, T.; Gutier-
rez, J. C. The chemokine SDF-1 is a chemoattractant forcontused spinal cord and does time of transplantation
human CD34+ hematopoietic progenitor cells and pro-make a difference? Do BMSCs migrate towards and
vides a new mechanism to explain the mobilization ofaway from the transplantation site and if so whereto? To CD34+ progenitors for peripheral blood. J. Exp. Med.
what extent do BMSCs differentiate when transplanted 185:111–120; 1997.
into the injured cord? Can grafted BMSCs support spi- 6. Azizi, S. A.; Stokes, D.; Augelli, B. J.; DiGirolamo, C.;
Prockop, D. J. Engraftment and migration of humannal cord repair and if so what mechanisms underlie the
bone marrow stromal cells implanted in the brains of al-biological effects? Based on the reported differences be-
bino rats-similarities to astrocyte grafts. Proc. Natl.tween in vitro and in vivo results, it is clear that the Acad. Sci. USA 95(7):3908–3913; 1998.influence of the milieu of the injured spinal cord on 7. Basso, D. M.; Beattie, M. S.; Bresnahan, J. C. A sensi-
BMSCs is not fully understood. This is a complicated tive and reliable locomotor rating scale for open field
testing in rats. J. Neurotrauma 12:1–21; 1995.issue because of the abundance and variety of factors in
8. Baumgartner, B. J.; Shine, H. D. Neuroprotection of spi-injured nervous tissue all with different effects on
nal motor neurons following targeted transduction withBMSC survival, migration, and differentiation.
an adenoviral vector carrying the gene for glial cell line-For transplantation purposes, it appears that differen- derived neurotrophic factor. Exp. Neurol. 153(1):102–
tiation of BMSCs prior to grafting would be best for 112; 1998.
9. Bethea, J. R.; Dietrich, W. D. Targeting the host inflam-effective repair for smaller, focal lesions of the spinal
matory response in traumatic spinal cord injury. Curr.cord or for specific aspects in larger, more routinely
Opin. Neurol. 15(3):355–360; 2002.seen, injuries. For instance, BMSC-derived oligodendro- 10. Bjornson, C. R.; Rietze, R. L.; Reynolds, B. A.; Magli,
cytes could be used to address specifically a demyelinat- M. C.; Vescovi, A. L. Turning brain into blood: A hema-
ing disease such as multiple sclerosis or the effects of topoietic fate adopted by adult neural stem cells in vivo.
Science 283:534–537; 1999.remyelination on functional restoration of the spinal
11. Black, I. B.; Woodbury, D. Adult rat and human bonecord after injury. Differentiation into neurons would
marrow stromal cells differentiate into neurons. Bloodallow addressing a motor neuron disease such as amyo- Cells Mol. Dis. 27(3):632–636; 2001.
trophic lateral sclerosis. However, is ex vivo differentia- 12. Bonavia, R.; Bajetto, A.; Barbero, S.; Pirani, P.; Florio,
tion of BMSCs prior to grafting in the spinal cord neces- T.; Schettini, G. Chemokines and their receptors in the
CNS: Expression of CXCL12/SDF-1 and CXCR4 andsary? In theory, the CNS environment may induce the
their role in astrocyte proliferation. Toxicol. Lett.cell to develop into the required cell type. Implantation
139(2–3):181–189; 2003.paradigms using undifferentiated BMSCs in vivo have 13. Bossolasco, P.; Cova, L.; Calzarossa, C.; Rimoldi, S. G.;
shown promise in the laboratory and clinical trials are Borsotti, C.; Lambertenghi Deliliers, G.; Silani, V.; Sol-
ongoing. igo, D. Neuroglial differentiation of human bone marrow
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